# Kura Oncology to Participate in Two Investor Conferences in November

- Published: 2026-11-13
- Author: [BiotechNews.io](https://biotechnews.io/author/biotechnews-io.md)
- Topics: [News](https://biotechnews.io/news.md)
- Source: https://biotechnews.io/news/kura-oncology-to-participate-in-two-investor-conferences-in-november/
- Publication: Biotech News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://biotechnews.io/editorial-policy/

SAN DIEGO, Nov. 13, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:

UBS Global Biopharma London Conference  
November 17, 2026  
1:20 p.m. GMT/ 8:20 a.m. ET / 5:20 a.m. PT

Jefferies Global Healthcare Conference  
November 18, 2026  
2:30 p.m. GMT/ 9:30 a.m. ET / 6:30 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at <a href="https://www.globenewswire.com/Tracker?data=N2geXPgeCI8RzkDx5O2ZPtzZBtQdGS_h4n1PS_MCrPg5PjEX6zVnoBYOj364FQuDpm5IxckzyTJRSOxlcRhjC2fOazI8-1i8GArH0-NhHAk=" rel="nofollow">https://kuraoncology.com/</a>, with archived replays available following the events.

**About Kura Oncology**  
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory *NPM1*\-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at <a href="https://www.globenewswire.com/Tracker?data=N2geXPgeCI8RzkDx5O2ZPtzZBtQdGS_h4n1PS_MCrPjVQSE5APkhusX6vdBSXlB3D3_ks2z81khvL9_K6YvIZZ_U2RGUj8quasv6Ty1JwteVkuTEJcILxp69cEr-j2t-VkSWbviAKm74Ta1vlgxyOVy-nxh4BdBZicqsyXdx3ivX72LpP10seVbevX38BwHuqkmSUHxFuMlzKdw55gzRoGRHqyh63NR8E7wV9IjIYrxnYXc69IqcTqDxiIZO0lIZJCV1kMiesZ95UfZP0zO5OA==" rel="nofollow">https://kuraoncology.com/</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=Fc1UUcLb0UYCfPbYnwwhBNKKoKuXnfIq5qBOB9fLv6YYA-quKvc1UmXNL31R0Lp4pyHCh4tc8XjBMQfLEc0-ABqYRj0rVhkK-a-PUz8fXRjxK5b-GE43Vu5f0c5DBnJ0uqzw-oNtHufH_Y0Dwy_SH48uvhUmOhoqAuwnBMR6v4kIHDnhdMPHIoJKImnKUP7gGzldmk-Wt5jY6lPS9rXxbA==" rel="nofollow">X</a> and <a href="https://www.globenewswire.com/Tracker?data=UBJ8xDGUkH0XcT8z7BJ9woXpQvR12GJ9gPHGybYc5j_z8haTCgqIJZrcCQQ_sTcErJbQzra2d0ldv5lbhoWOQiDLe-i7xtSZ3U9_yvM6kqcR2EkppFkt_zhSEtff9cWY" rel="nofollow">LinkedIn</a>.

**Kura Contact**

Investors and Media:  
Greg Mann  
<a href="https://www.globenewswire.com/Tracker?data=UWwQSVN__psot8hSqG1ONPI0UVOo4-V3abkrRnyws55N27yaTj70wA07ONUQdFYd3Li7cPTm_miO_QQv_7OIwEdJ7jxZs_oYB1cSXOpB4r0=" rel="nofollow">gmann@kuraoncology.com</a>

  
![](https://ml.globenewswire.com/media/MGNlMWZhMWMtZGIwNC00MDQzLTllYjAtM2U4NGI1M2Q5MjU2LTEwMjg3NjgtMjAyNi0xMS0xMy1lbg==/tiny/Kura-Oncology-Inc-.png)

## Related

- [Global AI Protein Design Market Report 2026-2033 | Generative AI Fuels 35.3% CAGR and a $20.9 Billion Biologics Opportunity by 2033](https://biotechnews.io/news/global-ai-protein-design-market-report-2026-2033-generative-ai-fuels-35-3-cagr-and-a-20-9.md)
- [COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering](https://biotechnews.io/news/cosciens-biopharma-inc-reports-q3-2026-results-and-provides-update-on-convertible-debentur.md)
- [Biorisk Management Service Market Size to Reach USD 4.91 Billion by 2033, Growing at 11.4% CAGR as Regulatory Compliance and Risk Assessment Demand Accelerates: Verified Market Research](https://biotechnews.io/news/biorisk-management-service-market-size-to-reach-usd-4-91-billion-by-2033-growing-at-11-4-c.md)
- [Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance](https://biotechnews.io/news/allarity-therapeutics-reports-third-quarter-2026-results-and-provides-full-year-2026-finan.md)